Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion type Assertion NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_head.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion description "[However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of proliferative skin disorders from keratosis pilaris-like and keratoacanthoma-like lesions to locally aggressive cutaneous squamous cell carcinoma (cuSCC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_provenance.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion evidence source_evidence_literature NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_provenance.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion SIO_000772 25185693 NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_provenance.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion wasDerivedFrom befree-2016 NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_provenance.
- NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_assertion wasGeneratedBy ECO_0000203 NP1216527.RAzaslB_zj65rDkPJNbK1i5LG3TIKQOS7bgrBPeh-5nUU130_provenance.